To amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products, and for other purposes.
Food and Drug Amendments of 2022
This bill reauthorizes Food and Drug Administration (FDA) user fee programs for certain drugs and devices, establishes requirements to increase diversity in clinical trials, and modifies requirements relating to the overall supply chain for drugs and devices.
Specifically, the bill reauthorizes through FY2027 the FDA user fee programs for prescription drugs, medical devices, generic drugs, and biosimilars.
The bill also requires the development of action plans and related reporting to increase the diversity of participants in clinical trials.
In addition, the bill requires the FDA to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why).
The bill also (1) establishes requirements and reauthorizes programs to support the development of specific categories of drugs and devices (e.g., pediatric drugs) and inspections of drug manufacturing facilities; and (2) establishes and revises requirements relating to the approval of drugs and devices, including requirements for postapproval studies and guidance about using real-world evidence to support drug and device applications.
Referred to the Subcommittee on Health.
Referred to the Subcommittee on Health.
Referred to the Subcommittee on Health.
Introduced in House
Introduced in House
Referred to the House Committee on Energy and Commerce.
Referred to the Subcommittee on Health.
Subcommittee Consideration and Mark-up Session Held.
Forwarded by Subcommittee to Full Committee (Amended) by the Yeas and Nays: 30 - 0 .
Committee Consideration and Mark-up Session Held.
Ordered to be Reported (Amended) by the Yeas and Nays: 55 - 0.
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 117-348.
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 117-348.
Placed on the Union Calendar, Calendar No. 262.
Mr. Pallone moved to suspend the rules and pass the bill, as amended.
checking server…
Ask anything about this bill. The AI reads the full text to answer.
Enter to send · Shift+Enter for new line
Referred to the Subcommittee on Health.
Referred to the Subcommittee on Health.
Referred to the Subcommittee on Health.
Referred to the House Committee on Energy and Commerce.
Referred to the House Committee on Energy and Commerce.
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Referred to the Subcommittee on Health.
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S2709)
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Referred to the Subcommittee on Health.
Considered under suspension of the rules. (consideration: CR H5298-5321)
DEBATE - The House proceeded with forty minutes of debate on H.R. 7667.
At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.
Considered as unfinished business. (consideration: CR H5402-5403)
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 392 - 28 (Roll no. 254).
Roll Call #254 (House)On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 392 - 28 (Roll no. 254). (text: 06/07/2022 CR H5298-5319)
Roll Call #254 (House)Motion to reconsider laid on the table Agreed to without objection.
Received in the Senate.